Scientists discover new role for miRNA in leukemia

Scientists here have found that mini-molecules called micro-RNA may play a critical role in the progression of chronic myeloid leukemia (CML) from its more treatable chronic phase to a life-threatening phase, called blast crisis.

Furthermore, they discovered an entirely new function for these molecules. The researchers show that microRNAs can sometimes directly control a protein’s function – not just whether or not the protein is made by the cell, as has been believed.

The study, using cells from CML patients in blast crisis, suggests that certain progenitor white blood cells are kept from maturing when levels of one microRNA, called miR-328, fall abnormally low. Immature white cells then build up in the blood and bone marrow, a telltale sign that the patient has entered the therapy-resistant blast-crisis phase.

The findings are being presented at the 2007 annual meeting of the American Society of Hematology (ASH), Dec. 8-11 in Atlanta.

“If verified, our study suggests that altering microRNA levels might represent a potentially new therapeutic strategy for CML patients who do not benefit from effective targeted agents such as imatinib (Gleevec) and dasatinib (Sprycel),” says principal investigator Danilo Perrotti, assistant professor of molecular virology, immunology and medical genetics and a researcher with the Ohio State University Comprehensive Cancer Center.

“The findings also reveal a new function for microRNAs, which should further our understanding of their role in cancer development and progression, and in normal cells.”

Researchers have known for some time that microRNAs bind to molecules called messenger RNA, which are part of the cell’s protein-making machinery, and in this way help regulate the types and amount of proteins made by cells.

But this study shows for the first time that the microRNA molecules sometimes bind directly with proteins themselves and affect their function.

In this case, a microRNA called miR-328 binds with a protein that, in blast phase CML, prevents immature blood cells from maturing. “We believe that miR-328 acts as a decoy molecule that normally ties up the protein, which enables the white blood cells to mature as they should,” Perrotti says.

During progression from chronic-phase to blast-crisis CML, however, the level of miR-328 falls, allowing the protein to be extremely active. This keeps the progenitor white blood cells from maturing, thus favoring blast-crisis conditions.

“These findings are important because they help us understand the biology of blast-crisis CML, and they may help unravel novel pathways responsible for the initiation and progression of leukemia generally,” Perrotti says.

Source: Ohio State University

Related stories:

Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in the June 9 issue of Cancer Cell.
Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.
In lab study, researchers find molecule that disrupts Ewing's sarcoma oncogene
Researchers at Georgetown University Medical Center have found a small molecule they say can block the action of the oncogene that causes Ewing's sarcoma, a rare cancer found in children and young adults. If further studies continue to prove beneficial, they say the novel agent could be the first targeted therapy to treat the disease, which can produce tumors anywhere in the body.
Researchers discover genetic cancer link between humans and dogs
Cancer researchers at the University of Minnesota and North Carolina State University have found that humans and dogs share more than friendship and companionship – they also share the same genetic basis for certain types of cancer. Furthermore, the researchers say that because of the way the genomes have evolved, getting cancer may be inevitable for some humans and dogs.
St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
Investigators at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development. The finding suggests for the first time that it may one day be possible for scientists to induce fully developed neurons to multiply and coax the injured brain to repair itself.
Genetics of imatinib resistance in acute lymphoblastic leukemia
In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children’s Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.
Novel M.S. Drug Shows Promise In Two Lethal Leukemias
A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.
Landmark study unlocks stem cell, DNA secrets to speed therapies
In a groundbreaking study led by an eminent molecular biologist at Florida State University, researchers have discovered that as embryonic stem cells turn into different cell types, there are dramatic corresponding changes to the order in which DNA is replicated and reorganized.

News discussion:

Medicine & Health news